Zoetis Inc. (ZTS) EV/Sales Ratio: 4.39x
Is Zoetis Inc.’s EV/Sales ratio high or low?
Zoetis Inc.'s EV/Sales ratio of 4.39x is 56% below its 5-year average of 9.90x, near the low end of its 5-year range (4.06x–15.91x).
The EV/Sales ratio for Zoetis Inc. (ZTS) is 4.39x as of Wednesday, June 10, 2026. It is below its 12-month average by 34.73% (6.73x).
ZTS EV/Sales Ratio Chart
ZTS Average EV/Sales Ratio Chart
ZTS Current vs Average EV/Sales Ratio Chart
ZTS EV/Sales Ratio Metrics
EV/SALES RATIO
4.39x
EV/SALES RATIO AVG TTM
6.73x
EV/SALES RATIO AVG 3Y
8.78x
EV/SALES RATIO AVG 5Y
9.90x
EV/SALES RATIO AVG 10Y
9.48x
EV/SALES RATIO AVG 15Y
8.30x
EV/SALES RATIO AVG 20Y
8.30x
CURRENT VS TTM AVG
-34.73%
CURRENT VS 3Y AVG
-49.99%
CURRENT VS 5Y AVG
-55.67%
CURRENT VS 10Y AVG
-53.71%
CURRENT VS 15Y AVG
-47.12%
CURRENT VS 20Y AVG
-47.12%
ZTS Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zoetis Inc. (ZTS) | — | 4.39x | 6.73x | 8.78x | 9.90x |
| Centene Corporation (CNC) | $31.94B | 0.14x | 0.11x | 0.20x | 0.29x |
| IQVIA Holdings Inc. (IQV) | $30.60B | 1.88x | 2.83x | 3.22x | 3.53x |
| Agilent Technologies, Inc. (A) | $38.26B | 5.53x | 5.56x | 5.75x | 6.21x |
| DexCom, Inc. (DXCM) | $29.24B | 6.23x | 6.64x | 10.22x | 13.89x |
| Biogen Inc. (BIIB) | $29.00B | 3.28x | 2.79x | 3.30x | 3.58x |
| Veeva Systems Inc. (VEEV) | $27.37B | 7.85x | 12.54x | 13.33x | 15.72x |
| Humana Inc. (HUM) | $43.78B | 0.39x | 0.30x | 0.40x | 0.54x |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 10.42x | 12.34x | 11.51x | 12.39x |
| Waters Corporation (WAT) | $23.83B | 9.32x | 7.03x | 7.13x | 7.32x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Zoetis Inc. EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Zoetis Inc. EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Zoetis Inc. (ZTS)?
- The EV/Sales ratio for ZTS stock is 4.39x.
- Is Zoetis Inc.'s EV/Sales ratio high or low?
- Zoetis Inc.'s EV/Sales ratio of 4.39x is 56% below its 5-year average of 9.90x, near the low end of its 5-year range (4.06x–15.91x).
- What is the TTM average EV/Sales ratio for Zoetis Inc. (ZTS)?
- The TTM average EV/Sales ratio for ZTS stock is 6.73x.
- What is the 3Y average EV/Sales ratio for Zoetis Inc. (ZTS)?
- The 3Y average EV/Sales ratio for ZTS stock is 8.78x.
- What is the 5Y average EV/Sales ratio for Zoetis Inc. (ZTS)?
- The 5Y average EV/Sales ratio for ZTS stock is 9.90x.
- What is the 10Y average EV/Sales ratio for Zoetis Inc. (ZTS)?
- The 10Y average EV/Sales ratio for ZTS stock is 9.48x.
- What is the 15Y average EV/Sales ratio for Zoetis Inc. (ZTS)?
- The 15Y average EV/Sales ratio for ZTS stock is 8.30x.
- What is the 20Y average EV/Sales ratio for Zoetis Inc. (ZTS)?
- The 20Y average EV/Sales ratio for ZTS stock is 8.30x.
Zoetis Inc. EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-10 | 4.39x |
| 2026-06-09 | 4.42x |
| 2026-06-08 | 4.27x |
| 2026-06-05 | 4.30x |
| 2026-06-04 | 4.30x |
| 2026-06-03 | 4.21x |
| 2026-06-02 | 4.16x |
| 2026-06-01 | 4.21x |
| 2026-05-29 | 4.22x |
| 2026-05-28 | 4.24x |
| 2026-05-27 | 4.30x |
| 2026-05-26 | 4.33x |
| 2026-05-22 | 4.38x |
| 2026-05-21 | 4.32x |
| 2026-05-20 | 4.31x |
| 2026-05-19 | 4.27x |
| 2026-05-18 | 4.22x |
| 2026-05-15 | 4.06x |
| 2026-05-14 | 4.12x |
| 2026-05-13 | 4.07x |
| 2026-05-12 | 4.19x |
| 2026-05-11 | 4.17x |
| 2026-05-08 | 4.45x |
| 2026-05-07 | 4.65x |
| 2026-05-06 | 5.91x |
| 2026-05-05 | 5.97x |
| 2026-05-04 | 5.98x |
| 2026-05-01 | 6.05x |
| 2026-04-30 | 6.09x |
| 2026-04-29 | 6.03x |
| 2026-04-28 | 6.16x |
| 2026-04-27 | 6.22x |
| 2026-04-24 | 6.17x |
| 2026-04-23 | 6.14x |
| 2026-04-22 | 6.20x |
| 2026-04-21 | 6.23x |
| 2026-04-20 | 6.44x |
| 2026-04-17 | 6.43x |
| 2026-04-16 | 6.27x |
| 2026-04-15 | 6.35x |
| 2026-04-14 | 6.37x |
| 2026-04-13 | 6.32x |
| 2026-04-10 | 6.22x |
| 2026-04-09 | 6.32x |
| 2026-04-08 | 6.31x |
| 2026-04-07 | 6.17x |
| 2026-04-06 | 6.24x |
| 2026-04-02 | 6.22x |
| 2026-04-01 | 6.19x |
| 2026-03-31 | 6.24x |
| 2026-03-30 | 6.15x |
| 2026-03-27 | 6.01x |
| 2026-03-26 | 6.16x |
| 2026-03-25 | 6.17x |
| 2026-03-24 | 6.13x |
| 2026-03-23 | 6.10x |
| 2026-03-20 | 6.12x |
| 2026-03-19 | 6.13x |
| 2026-03-18 | 6.20x |
| 2026-03-17 | 6.40x |
| 2026-03-16 | 6.23x |
| 2026-03-13 | 6.12x |
| 2026-03-12 | 6.11x |
| 2026-03-11 | 6.31x |
| 2026-03-10 | 6.34x |
| 2026-03-09 | 6.43x |
| 2026-03-06 | 6.38x |
| 2026-03-05 | 6.42x |
| 2026-03-04 | 6.59x |
| 2026-03-03 | 6.59x |
| 2026-03-02 | 6.73x |
| 2026-02-27 | 6.83x |
| 2026-02-26 | 6.77x |
| 2026-02-25 | 6.73x |
| 2026-02-24 | 6.72x |
| 2026-02-23 | 6.59x |
| 2026-02-20 | 6.73x |
| 2026-02-19 | 6.66x |
| 2026-02-18 | 6.74x |
| 2026-02-17 | 6.58x |
| 2026-02-13 | 6.63x |
| 2026-02-12 | 6.58x |
| 2026-02-11 | 6.62x |
| 2026-02-10 | 6.60x |
| 2026-02-09 | 6.56x |
| 2026-02-06 | 6.56x |
| 2026-02-05 | 6.53x |
| 2026-02-04 | 6.53x |
| 2026-02-03 | 6.33x |
| 2026-02-02 | 6.44x |
| 2026-01-30 | 6.44x |
| 2026-01-29 | 6.29x |
| 2026-01-28 | 6.30x |
| 2026-01-27 | 6.45x |
| 2026-01-26 | 6.40x |
| 2026-01-23 | 6.40x |
| 2026-01-22 | 6.42x |
| 2026-01-21 | 6.45x |
| 2026-01-20 | 6.36x |
| 2026-01-16 | 6.43x |
| 2026-01-15 | 6.46x |
| 2026-01-14 | 6.49x |
| 2026-01-13 | 6.43x |
| 2026-01-12 | 6.46x |
| 2026-01-09 | 6.55x |
| 2026-01-08 | 6.53x |
| 2026-01-07 | 6.48x |
| 2026-01-06 | 6.65x |
| 2026-01-05 | 6.65x |
| 2026-01-02 | 6.49x |
| 2025-12-31 | 6.49x |
| 2025-12-30 | 6.51x |
| 2025-12-29 | 6.49x |
| 2025-12-26 | 6.51x |
| 2025-12-24 | 6.47x |
| 2025-12-23 | 6.38x |
| 2025-12-22 | 6.39x |
| 2025-12-19 | 6.32x |
| 2025-12-18 | 6.34x |
| 2025-12-17 | 6.32x |
| 2025-12-16 | 6.36x |
| 2025-12-15 | 6.26x |
| 2025-12-12 | 6.15x |
| 2025-12-11 | 6.10x |
| 2025-12-10 | 6.12x |
| 2025-12-09 | 6.01x |
| 2025-12-08 | 6.13x |
| 2025-12-05 | 6.15x |
| 2025-12-04 | 6.23x |
| 2025-12-03 | 6.33x |
| 2025-12-02 | 6.42x |
| 2025-12-01 | 6.55x |
| 2025-11-28 | 6.60x |
| 2025-11-26 | 6.57x |
| 2025-11-25 | 6.58x |
| 2025-11-24 | 6.35x |
| 2025-11-21 | 6.31x |
| 2025-11-20 | 6.02x |
| 2025-11-19 | 6.07x |
| 2025-11-18 | 6.12x |
| 2025-11-17 | 6.16x |
| 2025-11-14 | 6.25x |
| 2025-11-13 | 6.27x |
| 2025-11-12 | 6.27x |
| 2025-11-11 | 6.22x |
| 2025-11-10 | 6.20x |
| 2025-11-07 | 6.22x |
| 2025-11-06 | 6.19x |
| 2025-11-05 | 6.23x |
| 2025-11-04 | 6.42x |
| 2025-11-03 | 7.42x |
| 2025-10-31 | 7.41x |
| 2025-10-30 | 7.41x |
| 2025-10-29 | 7.40x |
| 2025-10-28 | 7.47x |
| 2025-10-27 | 7.57x |
| 2025-10-24 | 7.50x |
| 2025-10-23 | 7.52x |
| 2025-10-22 | 7.55x |
| 2025-10-21 | 7.51x |
| 2025-10-20 | 7.46x |
| 2025-10-17 | 7.41x |
| 2025-10-16 | 7.37x |
| 2025-10-15 | 7.32x |
| 2025-10-14 | 7.38x |
| 2025-10-13 | 7.32x |
| 2025-10-10 | 7.27x |
| 2025-10-09 | 7.38x |
| 2025-10-08 | 7.38x |
| 2025-10-07 | 7.35x |
| 2025-10-06 | 7.47x |
| 2025-10-03 | 7.52x |
| 2025-10-02 | 7.52x |
| 2025-10-01 | 7.55x |
| 2025-09-30 | 7.52x |
| 2025-09-29 | 7.36x |
| 2025-09-26 | 7.38x |
| 2025-09-25 | 7.27x |
| 2025-09-24 | 7.30x |
| 2025-09-23 | 7.34x |
| 2025-09-22 | 7.44x |
| 2025-09-19 | 7.50x |
| 2025-09-18 | 7.55x |
| 2025-09-17 | 7.55x |
| 2025-09-16 | 7.57x |
| 2025-09-15 | 7.51x |
| 2025-09-12 | 7.61x |
| 2025-09-11 | 7.72x |
| 2025-09-10 | 7.66x |
| 2025-09-09 | 7.68x |
| 2025-09-08 | 7.77x |
| 2025-09-05 | 7.85x |
| 2025-09-04 | 7.84x |
| 2025-09-03 | 7.81x |
| 2025-09-02 | 7.83x |
| 2025-08-29 | 7.99x |
| 2025-08-28 | 7.92x |
| 2025-08-27 | 7.95x |
| 2025-08-26 | 7.92x |
| 2025-08-25 | 7.94x |
| 2025-08-22 | 8.01x |
| 2025-08-21 | 7.96x |
| 2025-08-20 | 8.01x |
| 2025-08-19 | 7.96x |
| 2025-08-18 | 7.80x |
| 2025-08-15 | 7.89x |
| 2025-08-14 | 7.84x |
| 2025-08-13 | 7.81x |
| 2025-08-12 | 7.68x |
| 2025-08-11 | 7.64x |
| 2025-08-08 | 7.57x |
| 2025-08-07 | 7.61x |
| 2025-08-06 | 7.52x |
| 2025-08-05 | 7.51x |
| 2025-08-04 | 7.87x |
| 2025-08-01 | 7.65x |
| 2025-07-31 | 7.58x |
| 2025-07-30 | 7.72x |
| 2025-07-29 | 7.83x |
| 2025-07-28 | 7.81x |
| 2025-07-25 | 7.88x |
| 2025-07-24 | 7.91x |
| 2025-07-23 | 7.94x |
| 2025-07-22 | 7.84x |
| 2025-07-21 | 7.65x |
| 2025-07-18 | 7.71x |
| 2025-07-17 | 7.78x |
| 2025-07-16 | 7.85x |
| 2025-07-15 | 7.92x |
| 2025-07-14 | 8.05x |
| 2025-07-11 | 8.02x |
| 2025-07-10 | 8.20x |
| 2025-07-09 | 8.18x |
| 2025-07-08 | 8.15x |
| 2025-07-07 | 8.12x |
| 2025-07-03 | 8.22x |
| 2025-07-02 | 8.22x |
| 2025-07-01 | 8.22x |
| 2025-06-30 | 8.07x |
| 2025-06-27 | 8.08x |
| 2025-06-26 | 8.06x |
| 2025-06-25 | 8.13x |
| 2025-06-24 | 8.15x |
| 2025-06-23 | 8.13x |
| 2025-06-20 | 8.12x |
| 2025-06-18 | 8.02x |
| 2025-06-17 | 8.34x |
| 2025-06-16 | 8.47x |
| 2025-06-13 | 8.47x |
| 2025-06-12 | 8.69x |
| 2025-06-11 | 8.57x |
| 2025-06-10 | 8.60x |
| 2025-06-09 | 8.48x |
| 2025-06-06 | 8.75x |
| 2025-06-05 | 8.68x |
| 2025-06-04 | 8.68x |
| 2025-06-03 | 8.76x |
| 2025-06-02 | 8.72x |
| 2025-05-30 | 8.68x |
| 2025-05-29 | 8.61x |
Showing the most recent 260 of 3,359 data points. The chart above shows the full history.
Related Metrics
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck